These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 31223050)

  • 1. QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
    J Recept Signal Transduct Res; 2019 Feb; 39(1):18-27. PubMed ID: 31223050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pamanji R; Yeguvapalli S
    J Recept Signal Transduct Res; 2018 Feb; 38(1):48-60. PubMed ID: 29369008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-based virtual screening, molecular docking, QSAR and pharmacophore analysis of quercetin-associated potential novel analogs against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
    J Recept Signal Transduct Res; 2017 Dec; 37(6):600-610. PubMed ID: 28958213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents.
    Minnelli C; Laudadio E; Mobbili G; Galeazzi R
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32138321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer.
    Minnelli C; Cianfruglia L; Laudadio E; Mobbili G; Galeazzi R; Armeni T
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach.
    Konidala KK; Bommu UD; Pabbaraju N
    J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigallocatechin gallate has pleiotropic effects on transmembrane signaling by altering the embedding of transmembrane domains.
    Ye F; Yang C; Kim J; MacNevin CJ; Hahn KM; Park D; Ginsberg MH; Kim C
    J Biol Chem; 2017 Jun; 292(24):9858-9864. PubMed ID: 28487468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.
    Shimizu M; Deguchi A; Lim JT; Moriwaki H; Kopelovich L; Weinstein IB
    Clin Cancer Res; 2005 Apr; 11(7):2735-46. PubMed ID: 15814656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening.
    Chaudhari P; Bari S
    Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Novel EGFR Inhibitors for the Targeted Therapy of Colorectal Cancer Using Pharmacophore Modelling, Docking, Molecular Dynamic Simulation and Biological Activity Prediction.
    Krishnan K A; Valavi SG; Joy A
    Anticancer Agents Med Chem; 2024; 24(4):263-279. PubMed ID: 38173208
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Imana SN; Ningsih EG; Tambunan USF
    Pak J Biol Sci; 2020 Mar; 23(4):567-574. PubMed ID: 32363843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative reverse docking strategy to identify potential antineoplastic targets of tea functional components and binding mode.
    Zheng R; Chen TS; Lu T
    Int J Mol Sci; 2011; 12(8):5200-12. PubMed ID: 21954353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction.
    Masuda M; Suzui M; Lim JT; Deguchi A; Soh JW; Weinstein IB
    J Exp Ther Oncol; 2002; 2(6):350-9. PubMed ID: 12440226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells.
    Liang YC; Lin-shiau SY; Chen CF; Lin JK
    J Cell Biochem; 1997 Oct; 67(1):55-65. PubMed ID: 9328839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of luteolin -7-glucoside and epicatechin gallate from
    Maiti P; Nand M; Joshi T; Ramakrishnan MA; Chandra S
    J Biomol Struct Dyn; 2021 Sep; 39(14):5048-5057. PubMed ID: 32579072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro and In Silico Studies of the Molecular Interactions of Epigallocatechin-3-
    Saeki K; Hayakawa S; Nakano S; Ito S; Oishi Y; Suzuki Y; Isemura M
    Molecules; 2018 May; 23(6):. PubMed ID: 29843451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
    Hamza A; Zhan CG
    J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
    Panicker PS; Melge AR; Biswas L; Keechilat P; Mohan CG
    Chem Biol Drug Des; 2017 Oct; 90(4):629-636. PubMed ID: 28303669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic oxindole derivatives:
    Maadwar S; Galla R
    J Recept Signal Transduct Res; 2019; 39(5-6):460-469. PubMed ID: 31814499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational and Biochemical Discovery of RSK2 as a Novel Target for Epigallocatechin Gallate (EGCG).
    Chen H; Yao K; Chang X; Shim JH; Kim HG; Malakhova M; Kim DJ; Bode AM; Dong Z
    PLoS One; 2015; 10(6):e0130049. PubMed ID: 26083344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.